Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: PTC Therapeutics, Inc.

Market Cap 6.72B 5.87B 5.43B 5.07B 9.51B 635B 9.58B 64.5B 25.1B 312B 25.21B 24.67B 1,084B P/E 2026 *
91.4x
P/E 2027 * 32.4x
Enterprise Value 4.93B 4.31B 3.99B 3.72B 6.98B 466B 7.04B 47.37B 18.43B 229B 18.52B 18.11B 796B EV / Sales 2026 *
4.2x
EV / Sales 2027 * 3.71x
Free-Float
92.62%
Yield 2026 *
-
Yield 2027 * -
1 day+2.51%
1 week+5.46%
Current month+9.63%
1 month+17.66%
3 months+23.98%
6 months+2.61%
Current year+6.58%
1 week 74.86
Extreme 74.865
81.71
1 month 67.16
Extreme 67.165
81.71
Current year 61.43
Extreme 61.43
81.71
1 year 43.18
Extreme 43.175
87.5
3 years 17.53
Extreme 17.53
87.5
5 years 17.53
Extreme 17.53
87.5
10 years 4.03
Extreme 4.03
87.5
Manager TitleAgeSince
Chief Executive Officer 54 22/03/2023
Director of Finance/CFO 41 13/07/2023
Chief Tech/Sci/R&D Officer - 01/10/2017
Director TitleAgeSince
Chairman 74 01/11/2004
Chairman 80 31/03/1998
Director/Board Member 65 01/12/2005
Date Insider Type Main position Quantity % Market Cap.
06-10Sell

Executive/Senior Manager

-56,409 0.0680%
05-15Fiscal year

General Counsel

8,436 0.0102%
05-14Sell

Chief Executive Officer

-12,572 0.0152%
Change 5-day change 1-year change 3-year change Capi.($)
+2.51%+5.46%+61.27%+93.13% 6.72B
+0.32%-2.41%+44.49%+140.80% 983B
+1.27%-1.85%+54.41%+39.65% 557B
+6.25%+3.80%+24.13%+67.39% 406B
+1.11%-1.93%+23.33%+16.35% 314B
+1.70%+1.90%+29.90%+18.51% 273B
+1.56%+2.14%+28.59%+34.81% 272B
+1.85%+9.53%-31.88%-43.59% 203B
+2.11%-1.66%+19.14%+50.10% 186B
+0.90%+0.46%+15.09%+59.86% 155B
Average +1.44%-0.28%+26.85%+47.70% 335.71B
Weighted average by Cap. +1.05%-2.20%+31.86%+64.90%

Financials

2026 *2027 *
Net sales 1.17B 1.03B 948M 885M 1.66B 111B 1.67B 11.27B 4.38B 54.51B 4.41B 4.31B 189B 1.31B 1.15B 1.06B 990M 1.86B 124B 1.87B 12.61B 4.9B 60.98B 4.93B 4.82B 212B
Net income 65.46M 57.2M 52.91M 49.38M 92.7M 6.19B 93.38M 629M 245M 3.04B 246M 240M 10.57B 178M 155M 144M 134M 252M 16.81B 254M 1.71B 665M 8.26B 668M 653M 28.71B
Net Debt -1.78B -1.56B -1.44B -1.35B -2.53B -169B -2.54B -17.13B -6.67B -82.88B -6.7B -6.55B -288B -1.84B -1.61B -1.49B -1.39B -2.61B -174B -2.63B -17.68B -6.88B -85.5B -6.91B -6.76B -297B
Logo PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Employees
991
Date Price Change Volume
22/06/26 $80.96 +2.51% 2,414,051
18/06/26 $78.98 +0.57% 2,870,286
17/06/26 $78.53 +7.18% 3,183,591
16/06/26 $73.27 -4.56% 6,044,172
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
80.96USD
Average target price
93.93USD
Spread / Average Target
+16.02%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTCT Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!